• pagcor slot
  • pagcor slot online
  • tol777
  • slot tol777
  • tol777
  • slot tol777
  • tol777
  • slot tol777
  • rom88
  • slot rom88
  • Drug Pricing

    Commentary

    The Anti-Competitive Middlemen Harming Pharmacies And Patients

    Astonishing drug innovations are improving the lives of patients including those living with cancer and autoimmune disorders. These innovations also expose the payment system’s fundamental flaws. The Federal Trade Commission’s (FTC) recently released interim report on pharmacy middlemen demonstrates that these flaws impose a high cost on patients and neighborhood pharmacies. These ...
    Commentary

    Read the latest on pharmaceutical benefit managers

    Legislation Urgently Needed to Rein In Pharmacy Benefit Mgrs.

    The U.S. House Committee on Oversight and Accountability held a hearing last month with the CEOs of the nation’s three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The hearing coincided with a new report from the committee on the outsized role these prescription-drug middlemen play in determining what people pay for ...
    Commentary

    Read the latest on the 340B Drug Pricing Program

    Reforming 340B to Serve the Interests of Patients, Not Institutions

    By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
    Commentary

    We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.

    Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla. The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the ...
    Commentary

    Fix the 340B Program to Increase Access to Medicine

    House lawmakers recently introduced legislation that would at last repair a program meant to provide low-income Americans with affordable medicine. In theory, the federal 340B Program, named after the section of the 1992 law establishing it, allows hospitals serving underprivileged groups to buy medications at steep discounts. The idea was ...
    Commentary

    Small-Molecule Price Controls Are Short-Sighted

    There’s never been a better time to get lung cancer in the United States. That may sound morbid. But this deadliest of cancers appears to be losing a bit of its punch. The combination of smoking reduction, increased screening, and pharmaceutical advancements has caused the lung cancer death rate to drop 20% over ...
    Commentary

    Learn about Sen. Sanders' latest scheme to cut drug prices

    Why Bernie Sanders’ Ozempic crusade is misguided

    Wouldn’t it be nice if we didn’t have to pay for the things we want? That’s the long and short of U.S. Sen. Bernie Sanders’ latest harebrained scheme to cut drug prices. In the Vermont independent’s capacity as chairman of the Senate Health, Education, Labor and Pensions Committee, Sanders sent ...
    Commentary

    Read the latest on drug innovation

    How The FDA’s Sunscreen Skepticism Burns Americans

    Every day, nearly 10,000 people in the United States are diagnosed with skin cancer. The good news is that applying sunscreen can substantially reduce a person’s risk of getting skin cancer. The bad news is that the federal government is doing its best to keep effective sunscreens out of the hands of ...
    Commentary

    Read the latest on drug pricing

    Insulin Prices Fall, Democrats Respond With Denial

    For years, the left’s campaign to dictate the price of prescription drugs has focused on one medicine above all others — insulin. The hormone was discovered more than a century ago by Canadian doctor Frederick Banting and his medical student Charles Best. They famously sold their patent to the University of ...
    Commentary

    Don’t Import British Methods For Rationing Access To Drugs

    Earlier this year, European authorities recommended approval of tofersen, a new drug that treats a rare genetic form of amyotrophic lateral sclerosis, or ALS. That decision came nearly a year after American regulators granted the drug accelerated approval. Patients with that rare form of ALS in England aren’t so lucky. The National Institute for ...
    Commentary

    The Anti-Competitive Middlemen Harming Pharmacies And Patients

    Astonishing drug innovations are improving the lives of patients including those living with cancer and autoimmune disorders. These innovations also expose the payment system’s fundamental flaws. The Federal Trade Commission’s (FTC) recently released interim report on pharmacy middlemen demonstrates that these flaws impose a high cost on patients and neighborhood pharmacies. These ...
    Commentary

    Read the latest on pharmaceutical benefit managers

    Legislation Urgently Needed to Rein In Pharmacy Benefit Mgrs.

    The U.S. House Committee on Oversight and Accountability held a hearing last month with the CEOs of the nation’s three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The hearing coincided with a new report from the committee on the outsized role these prescription-drug middlemen play in determining what people pay for ...
    Commentary

    Read the latest on the 340B Drug Pricing Program

    Reforming 340B to Serve the Interests of Patients, Not Institutions

    By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
    Commentary

    We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.

    Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla. The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the ...
    Commentary

    Fix the 340B Program to Increase Access to Medicine

    House lawmakers recently introduced legislation that would at last repair a program meant to provide low-income Americans with affordable medicine. In theory, the federal 340B Program, named after the section of the 1992 law establishing it, allows hospitals serving underprivileged groups to buy medications at steep discounts. The idea was ...
    Commentary

    Small-Molecule Price Controls Are Short-Sighted

    There’s never been a better time to get lung cancer in the United States. That may sound morbid. But this deadliest of cancers appears to be losing a bit of its punch. The combination of smoking reduction, increased screening, and pharmaceutical advancements has caused the lung cancer death rate to drop 20% over ...
    Commentary

    Learn about Sen. Sanders' latest scheme to cut drug prices

    Why Bernie Sanders’ Ozempic crusade is misguided

    Wouldn’t it be nice if we didn’t have to pay for the things we want? That’s the long and short of U.S. Sen. Bernie Sanders’ latest harebrained scheme to cut drug prices. In the Vermont independent’s capacity as chairman of the Senate Health, Education, Labor and Pensions Committee, Sanders sent ...
    Commentary

    Read the latest on drug innovation

    How The FDA’s Sunscreen Skepticism Burns Americans

    Every day, nearly 10,000 people in the United States are diagnosed with skin cancer. The good news is that applying sunscreen can substantially reduce a person’s risk of getting skin cancer. The bad news is that the federal government is doing its best to keep effective sunscreens out of the hands of ...
    Commentary

    Read the latest on drug pricing

    Insulin Prices Fall, Democrats Respond With Denial

    For years, the left’s campaign to dictate the price of prescription drugs has focused on one medicine above all others — insulin. The hormone was discovered more than a century ago by Canadian doctor Frederick Banting and his medical student Charles Best. They famously sold their patent to the University of ...
    Commentary

    Don’t Import British Methods For Rationing Access To Drugs

    Earlier this year, European authorities recommended approval of tofersen, a new drug that treats a rare genetic form of amyotrophic lateral sclerosis, or ALS. That decision came nearly a year after American regulators granted the drug accelerated approval. Patients with that rare form of ALS in England aren’t so lucky. The National Institute for ...
    Scroll to Top